Mildenberger, Eva; Wackernagel, Dirk; Schuster, Alexander K. et al.
Changes in neonatal care Implications for ophthalmological careOPHTHALMOLOGIE. 2023
Mora, Jaume; Chan, Godfrey Chi Fung; Morgenstern, Daniel et al.
CHARACTERIZATION OF ONSET AND RESOLUTION OF ADVERSE EVENTS IN PATIENTS TREATED WITH NAXITAMAB IN TRIAL 201PEDIATRIC BLOOD & CANCER. Bd. 70. 2023 S. S561-S561
Kleinle, Stephanie; Scholz, Veronika; Benet-Pages, Anna et al.
Closing the Gap - Detection of 5q-Spinal Muscular Atrophy by Short-Read Next-Generation Sequencing and Unexpected Results in a Diagnostic Patient CohortJOURNAL OF NEUROMUSCULAR DISEASES. Bd. 10. H. 5. 2023 S. 835-846
Maier, Esther M.; Muetze, Ulrike; Janzen, Nils et al.
Collaborative evaluation study on 18 candidate diseases for newborn screening in 1.77 million samplesJOURNAL OF INHERITED METABOLIC DISEASE. 2023
Casabona, Giacomo; Berton, Olivia; Singh, Tina et al.
Combined measles-mumps-rubella-varicella vaccine and febrile convulsions: the risk considered in the broad contextEXPERT REVIEW OF VACCINES. Bd. 22. H. 1. 2023 S. 764-776
Zepp, Fred; Berner, Reinhard
Communication in pediatrics-Prospects and limits in the age of the information revolutionMONATSSCHRIFT KINDERHEILKUNDE. Bd. 171. H. 10. 2023 S. 866-870
Alkassar, Muhnnad; Engelhardt, Sophia; Abu-Tair, Tariq et al.
Comparative Study of 2D-Cine and 3D-wh Volumetry: Revealing Systemic Error of 2D-Cine VolumetryDIAGNOSTICS. Bd. 13. H. 20. 2023
Auzanneau, Marie; Kieninger, Dorothee M.; Laubner, Katharina et al.
Comparison of BMI and HbA1c changes before and during the COVID-19 pandemic in type 1 diabetes: a longitudinal population-based studyJOURNAL OF DIABETES AND METABOLIC DISORDERS. 2023
Kaps, Leonard; Medina-Montano, Carolina; Bros, Matthias et al.
Comparison of Inflammatory Cytokine Levels in Hepatic and Jugular Veins of Patients with CirrhosisMEDIATORS OF INFLAMMATION. Bd. 2023. 2023
Wasserstein, Melissa P.; Lachmann, Robin; Hollak, Carla et al.
Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trialORPHANET JOURNAL OF RARE DISEASES. Bd. 18. H. 1. 2023